menu
    • menu
    [{"orgOrder":0,"company":"Korro Bio","sponsor":"Wu Capital","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Series A Financing","leadProduct":"RNA editing therapies","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Korro Bio","amount2":0.089999999999999997,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0.089999999999999997,"dosageForm":"","sponsorNew":"Korro Bio \/ Wu Capital","highestDevelopmentStatusID":"4","companyTruncated":"Korro Bio \/ Wu Capital"},{"orgOrder":0,"company":"Korro Bio","sponsor":"Eventide Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2022","type":"Series B Financing","leadProduct":"Genetic Medicine","moa":"","graph1":"Genetic Disease","graph2":"Discovery","graph3":"Korro Bio","amount2":0.12,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Genetic Disease","amount2New":0.12,"dosageForm":"","sponsorNew":"Korro Bio \/ Eventide Asset Management","highestDevelopmentStatusID":"2","companyTruncated":"Korro Bio \/ Eventide Asset Management"},{"orgOrder":0,"company":"Korro Bio","sponsor":"Genevant Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"RNA-based Therapeutic","moa":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Korro Bio","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Korro Bio \/ Genevant Sciences","highestDevelopmentStatusID":"1","companyTruncated":"Korro Bio \/ Genevant Sciences"},{"orgOrder":0,"company":"Korro Bio","sponsor":"Frequency Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Merger","leadProduct":"Undisclosed","moa":"","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Korro Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Korro Bio \/ Korro Bio","highestDevelopmentStatusID":"3","companyTruncated":"Korro Bio \/ Korro Bio"},{"orgOrder":0,"company":"Korro Bio","sponsor":"Frequency Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2023","type":"Merger","leadProduct":"Undisclosed","moa":"","graph1":"Genetic Disease","graph2":"Discovery Platform","graph3":"Korro Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Korro Bio \/ Korro Bio","highestDevelopmentStatusID":"3","companyTruncated":"Korro Bio \/ Korro Bio"},{"orgOrder":0,"company":"Korro Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"KRRO-110","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Korro Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Korro Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Korro Bio \/ Not Applicable"},{"orgOrder":0,"company":"Korro Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"KRRO-110","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Korro Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Korro Bio \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Korro Bio \/ Not Applicable"},{"orgOrder":0,"company":"Korro Bio","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Large molecule","year":"2024","type":"Private Placement","leadProduct":"KRRO-110","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Korro Bio","amount2":0.070000000000000007,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"Korro Bio \/ Deep Track Capital","highestDevelopmentStatusID":"4","companyTruncated":"Korro Bio \/ Deep Track Capital"},{"orgOrder":0,"company":"Korro Bio","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"RNA-based Therapy","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Korro Bio","amount2":0.53000000000000003,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Korro Bio \/ Novo Nordisk","highestDevelopmentStatusID":"14","companyTruncated":"Korro Bio \/ Novo Nordisk"}]

    Find Clinical Drug Pipeline Developments & Deals by Korro Bio

    Menu

    Korro Bio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Korro Bio

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Korro Bio

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RNA-based Therapy

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Discovery Platform

                            Sponsor : Novo Nordisk

                            Deal Size : $530.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Korro Bio Announces Collaboration with Novo Nordisk to Develop Two Therapeutic Candidates

                            Details : The collaboration brings together Novo's deep cardiometabolic disease understanding and drug development experience with Korro’s platform to develop RNA editing product candidates.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            September 16, 2024

                            Lead Product(s) : RNA-based Therapy

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Discovery Platform

                            Sponsor : Novo Nordisk

                            Deal Size : $530.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Korro Bio

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Korro Bio

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KRRO-110

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Sponsor : Deep Track Capital

                            Deal Size : $70.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Korro Announces $70 Million Private Placement

                            Details : The net proceeds will be used to support the clinical advancement of Korro's lead product KRRO-110 for treating patients suffering from alpha-1 antitrypsin deficiency.

                            Brand Name : KRRO-110

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 18, 2024

                            Lead Product(s) : KRRO-110

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Sponsor : Deep Track Capital

                            Deal Size : $70.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Korro Bio

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Korro Bio

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KRRO-110

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Korro Highlights Data for AAT and RNA Editing Program Progress

                            Details : KRRO-110 is based on Korro’s proprietary RNA editing platform, OPERA™. It is being evaluated in preclinical studies for the treatment of Alpha-1 Antitrypsin Deficiency.

                            Brand Name : KRRO-110

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 18, 2024

                            Lead Product(s) : KRRO-110

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Korro Bio

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Korro Bio

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KRRO-110

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Korro Announces Selection of its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsi...

                            Details : KRRO-110 is an oligonucleotide restorator, which works by targeting A1AT protein, it is being investigated for the treatment of Alpha-1 Antitrypsin Deficiency.

                            Brand Name : KRRO-110

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 07, 2023

                            Lead Product(s) : KRRO-110

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Korro Bio

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Korro Bio

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Study Phase : Discovery Platform

                            Recipient : Frequency Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            UPDATE: Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million

                            Details : The combined company will focus on the advancement of Korro Bio’s portfolio of RNA editing programs including, OPERA platform which harnesses the body’s natural base editing system, specifically ADAR, to make targeted edits to a single RNA base.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 03, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Discovery Platform

                            Recipient : Frequency Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Korro Bio

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Korro Bio

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Study Phase : Discovery Platform

                            Recipient : Frequency Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Korro Bio and Frequency Therapeutics Announce Merger Agreement

                            Details : The combined company will focus on the advancement of Korro Bio’s portfolio of RNA editing programs including, OPERA platform which harnesses the body’s natural base editing system, specifically ADAR, to make targeted edits to a single RNA base.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            July 14, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Discovery Platform

                            Recipient : Frequency Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Korro Bio

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Korro Bio

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RNA-based Therapeutic

                            Therapeutic Area : Genetic Disease

                            Study Phase : Undisclosed

                            Sponsor : Genevant Sciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Korro Bio and Genevant Sciences Enter into Collaboration Agreement to Develop RNA Editing Therapeutic for Alph...

                            Details : The Collaboration to combine Korro’s RNA editing technology with Genevant’s industry-leading LNP technology to develop a differentiated therapeutic option for patients with Alpha-1 Antitrypsin Deficiency (AATD).

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            March 07, 2023

                            Lead Product(s) : RNA-based Therapeutic

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Undisclosed

                            Sponsor : Genevant Sciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Korro Bio

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Korro Bio

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Genetic Medicine

                            Therapeutic Area : Genetic Disease

                            Study Phase : Discovery

                            Sponsor : Eventide Asset Management

                            Deal Size : $116.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Korro Bio Completes $116M Series B Financing to Expand the Frontier of Genetic Medicine through its Pipeline o...

                            Details : The financing will enable Korro to advance its lead program in development for patients with Alpha-1 Antitrypsin Deficiency (AATD), an inherited genetic disorder leading to liver and lung disease with RNA editing platform.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            January 05, 2022

                            Lead Product(s) : Genetic Medicine

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Discovery

                            Sponsor : Eventide Asset Management

                            Deal Size : $116.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Korro Bio

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed

                            Korro Bio

                            U.S.A arrow
                            Fi Europe 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RNA editing therapies

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Sponsor : Wu Capital

                            Deal Size : $91.5 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Korro Bio Closes $91.5 Million Series A Financing to Advance the Next Frontier in RNA Therapeutics

                            Details : This financing enables Korro to advance its lead program to IND filing and establish a broad portfolio of innovative RNA editing therapies. Korro’s OPERA platform, harnesses the body’s natural base editing system, specifically ADAR to make targeted e...

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            September 10, 2020

                            Lead Product(s) : RNA editing therapies

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Sponsor : Wu Capital

                            Deal Size : $91.5 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth